Ausupreme International Holdings Limited (Stock Code: 2031) published its unaudited interim results for the six months ended 30 September 2025. The group recorded a revenue of HK$144.97 million, up 14.6% from HK$126.54 million in the same period last year. Profit for the period reached HK$17.90 million, a 35.2% increase from HK$13.24 million in 2024.

Management attributed the positive performance to new product launches, a rise in sales outlets, and a focused advertising and promotional strategy. According to the report, health supplement products continued to dominate revenue, accounting for HK$138.59 million, while personal care products and honey products contributed HK$5.96 million and HK$0.43 million, respectively.

By sales channel, consignment counters achieved HK$105.18 million in revenue, specialty stores brought in HK$23.20 million, e-commerce generated HK$10.72 million, and other avenues recorded HK$5.88 million. Gross profit increased correspondingly, holding steady at around 87.5% of revenue.

Selling and distribution expenses grew to HK$87.28 million, and general and administrative expenses rose to HK$18.70 million. Both increases reflected higher sales-related costs and the additional depreciation of right-of-use assets. Finance costs included HK$0.03 million in bank borrowing interest and HK$0.47 million in lease liabilities.

As of 30 September 2025, cash and time deposits amounted to HK$101.24 million, while net current assets stood at HK$115.40 million. The board declined to declare an interim dividend. A final dividend for the year ended 31 March 2025, at HK2 cents per share, was paid on 8 October 2025.

In the face of global economic challenges and evolving consumer behavior, Ausupreme International Holdings Limited intends to further refine its product offerings and marketing strategies to bolster growth and market position in the health and personal care sector.